BR112021024848A2 - Métodos de purificação de anticorpos e composições dos mesmos - Google Patents

Métodos de purificação de anticorpos e composições dos mesmos

Info

Publication number
BR112021024848A2
BR112021024848A2 BR112021024848A BR112021024848A BR112021024848A2 BR 112021024848 A2 BR112021024848 A2 BR 112021024848A2 BR 112021024848 A BR112021024848 A BR 112021024848A BR 112021024848 A BR112021024848 A BR 112021024848A BR 112021024848 A2 BR112021024848 A2 BR 112021024848A2
Authority
BR
Brazil
Prior art keywords
compositions
purification methods
antibody purification
antibody
methods
Prior art date
Application number
BR112021024848A
Other languages
English (en)
Portuguese (pt)
Inventor
George Parks
Lutfiye Kurt
E Dolan Michael
Norbert Schuelke
F Oppenheim Sheldon
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BR112021024848A2 publication Critical patent/BR112021024848A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112021024848A 2019-06-10 2020-06-10 Métodos de purificação de anticorpos e composições dos mesmos BR112021024848A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962859580P 2019-06-10 2019-06-10
PCT/US2020/037069 WO2020252072A1 (en) 2019-06-10 2020-06-10 Antibody purification methods and compositions thereof

Publications (1)

Publication Number Publication Date
BR112021024848A2 true BR112021024848A2 (pt) 2022-01-18

Family

ID=73782230

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024848A BR112021024848A2 (pt) 2019-06-10 2020-06-10 Métodos de purificação de anticorpos e composições dos mesmos

Country Status (14)

Country Link
US (1) US20220259291A1 (cg-RX-API-DMAC7.html)
EP (1) EP3980119A4 (cg-RX-API-DMAC7.html)
JP (2) JP7753105B2 (cg-RX-API-DMAC7.html)
CN (4) CN114025843B (cg-RX-API-DMAC7.html)
AR (1) AR119268A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020290999B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021024848A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143169A1 (cg-RX-API-DMAC7.html)
IL (1) IL288830A (cg-RX-API-DMAC7.html)
MA (1) MA56132A (cg-RX-API-DMAC7.html)
MX (1) MX2021015302A (cg-RX-API-DMAC7.html)
PL (1) PL439807A1 (cg-RX-API-DMAC7.html)
TW (1) TW202112800A (cg-RX-API-DMAC7.html)
WO (1) WO2020252072A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12024561B2 (en) * 2018-04-10 2024-07-02 Dr. Reddy's Laboratories Limited Stable antibody formulation
EP4380948A4 (en) * 2021-08-05 2025-07-16 Dr Reddys Laboratories Ltd METHOD FOR PURIFYING AN ANTIBODY COMPOSITION BY MEANS OF CATION EXCHANGE CHROMATOGRAPHY
US20240400610A1 (en) * 2021-09-03 2024-12-05 Dr. Reddy's Laboratories Limited Method to obtain a purified antibody composition
WO2023180523A1 (en) * 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
ES2377979T3 (es) * 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US9994609B2 (en) * 2013-03-15 2018-06-12 Biogen Ma Inc. Hydrophobic interaction protein chromatography under no-salt conditions
EP3116891B1 (en) * 2014-03-10 2020-02-12 Richter Gedeon Nyrt. Immunoglobulin purification using pre-cleaning steps
WO2018104893A1 (en) * 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life

Also Published As

Publication number Publication date
AU2020290999A1 (en) 2022-02-03
MX2021015302A (es) 2022-01-18
PL439807A1 (pl) 2022-12-05
AU2020290999B2 (en) 2026-06-18
CN118909119A (zh) 2024-11-08
IL288830A (en) 2022-02-01
JP7879309B2 (ja) 2026-06-23
CN114025843A (zh) 2022-02-08
AR119268A1 (es) 2021-12-09
JP2022536659A (ja) 2022-08-18
JP2025087720A (ja) 2025-06-10
US20220259291A1 (en) 2022-08-18
EP3980119A4 (en) 2023-06-07
EP3980119A1 (en) 2022-04-13
CN118909120A (zh) 2024-11-08
TW202112800A (zh) 2021-04-01
MA56132A (fr) 2022-04-13
WO2020252072A1 (en) 2020-12-17
CN114025843B (zh) 2026-01-09
CA3143169A1 (en) 2020-12-17
JP7753105B2 (ja) 2025-10-14
CN118909121A (zh) 2024-11-08
AU2026204169A1 (en) 2026-06-18

Similar Documents

Publication Publication Date Title
MX2021015302A (es) Metodos de purificacion de anticuerpos y composiciones de estos.
SA520420458B1 (ar) نظائر رابامايسين مرتبطة بـ C40، C28، وC32 mTOR كمثبطات
BR112021023345A2 (pt) Imunotolerância com alvo em madcam
MX2021015300A (es) Métodos de producción de un anticuerpo anti-¿4¿7.
AR114283A1 (es) Receptores quiméricos de dll3 y métodos para su uso
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
EA201992232A1 (ru) Композиции и способы для иммуноонкологии
BR112018075516A2 (pt) purificação de anticorpos multiespecíficos
ZA201804654B (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
JOP20190066B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
EA201891532A1 (ru) Композиции и способы лечения гемоглобинопатий
EA201691581A1 (ru) Способы и композиции для повышения эффективности направленной модификации генов с применением опосредованной олигонуклеотидами репарации генов
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
WO2016033225A3 (en) Antibodies, compositions, and uses
EA201171018A1 (ru) Биореактор для культивирования клеток млекопитающих
SA523451582B1 (ar) Ccr8 الأجسام المضادة لـ
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
MX351799B (es) 2-oxo-1,3-dioxolan-4-carboxamidas, su preparacion y uso.
PL439808A1 (pl) Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał
EA201890572A1 (ru) Биофармацевтические композиции
MX2023012325A (es) Anticuerpos anti-tslp modificados.
AR119858A1 (es) Bacilos de temperatura optimizada
TR201914501A2 (tr) Aeroponi̇k i̇ç ortam bi̇tki̇ yeti̇şti̇rme modülleri̇
EA201791233A1 (ru) Материал стволовых клеток и способ его получения
EA201390639A1 (ru) Производные 2-пиперазин-1-ил-4н-1,3-бензотиазин-4-она и их применение для лечения инфекций у млекопитающих

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024018491-5 PROTOCOLO 870240077055 EM 09/09/2024 11:33.